Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Marie José Kersten, Kirsten Saevels, Evelyne Willems, Marte C. Liefaard, Stavros Milatos, Margot J. Pont, Claire Vennin, Eva Santermans, Anna D. D. van Muyden, Jeevan Shetty, Esmée P. Hoefsmit, Omotayo Fasan, Maria T. Kuipers, Sébastien Anguille, Joost S.P. Vermaat

Blood (2024) 144 (Supplement 1): 93.

https://doi.org/10.1182/blood-2024-205360

Published: 2024

Journal Articles

Population-Based External Validation of the CAR-Hematotox Score to Predict CAR T Cell Related Toxicity and Outcome in R/R LBCL Patients

Blood (2024) 144 (Supplement 1): 1747.

https://doi.org/10.1182/blood-2024-209879

Published: 2024

Journal Articles

Unveiling Transformation Mechanisms of Nodal Marginal Zone Lymphoma Using a Multi-Omics Approach

Johanna A.A. Bult, Yujie Zhong, Fleur A. De Groot, Ruben A.L. De Groen, Nick Veltmaat, Diana Al-Sarayfi, Wouter Plattel, Joost L. Kluiver, Anke Van Den Berg, Stefano Rosati, Arjan Diepstra, Joost S.P. Vermaat, Marcel Nijland

Blood (2024) 144 (Supplement 1): 2984.

https://doi.org/10.1182/blood-2024-206997

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

Lori A. Leslie, Chan Y. Cheah, Franck Morschhauser, Justin M. Darrah, Joshua Brody, David Belada, Juraj Duras, Joost S.P. Vermaat, Gerardo Musuraca, Kojo Osei-Bonsu, Yi Hao, Kimberly G. Archer, Monica Wielgos-Bonvallet, Ali Rana, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 3106.

https://doi.org/10.1182/blood-2024-199652

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab + R 2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

Blood (2024) 144 (Supplement 1): 342.

https://doi.org/10.1182/blood-2024-200262

Published: 2024

Journal Articles

Cell-Free DNA Genomic and Fragmentomic Features for Early Outcome Prediction in Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1588.

https://doi.org/10.1182/blood-2024-206636

Published: 2024

Journal Articles

Oncogenic CARD11 Mutations and Autonomous BCR Signaling Act As Functionally Equivalent Alternative Drivers in ABC-DLBCL

Janneke Eken, Fleur R.M. Havenaar, Edwin Quinten, Ruben A.L. De Groen, Julieta Sepulveda-Yanez, Joost S.P. Vermaat, Cornelis A.M. van Bergen, Hendrik Veelken

Blood (2024) 144 (Supplement 1): 1619.

https://doi.org/10.1182/blood-2024-204704

Published: 2024

Journal Articles

Immunosuppressed Tumor Microenvironment in MYC -Rearranged High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

Blood (2024) 144 (Supplement 1): 4380.

https://doi.org/10.1182/blood-2024-205968

Published: 2024

Journal Articles

DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial

Blood (2023) 142 (Supplement 1): 3090.

https://doi.org/10.1182/blood-2023-181707

Published: 2023

Journal Articles

Epcoritamab SC + R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: First Disclosure from Arm 8 of the Epcore NHL-2 Trial

Joost S.P Vermaat, Joshua Brody, Juraj Ďuraš, Yasmin H. Karimi, Chan Y. Cheah, Justin M. Darrah, Gerardo Musuraca, Franck Morschhauser, Daniela Hoehn, Ali Rana, Yaou Song, Pegah Jafarinasabian, David Belada

Blood (2023) 142 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2023-180935

Published: 2023

Journal Articles

Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5101) in Relapsed/Refractory NHL: Results from the Phase 1 Atalanta-1 Trial

Marie José Kersten, Kirsten Saevels, Yves Beguin, Joost S.P Vermaat, Nadia Verbruggen, Maike Spoon, Marte C. Liefaard, Margot Pont, Anna D.D. van Muyden, Maria T. Kuipers, Sébastien Anguille

Blood (2023) 142 (Supplement 1): 2113.

https://doi.org/10.1182/blood-2023-172736

Published: 2023

Journal Articles

Molecular Diagnostics for TP53 Is Recommended in B-Cell Lymphomas

Lorraine M. De Haan, Ruben A.L. De Groen, Fleur de Groot, Troy Noordenbos, Tom van Wezel, Ronald van Eijk, Dina Ruano, Arjan Diepstra, Lianne Koens, Aniko Sijs-Szabo, Hendrik Veelken, Arjen Cleven, Patty M. Jansen, Joost S.P. Vermaat

Blood (2022) 140 (Supplement 1): 11916–11918.

https://doi.org/10.1182/blood-2022-163197

Published: 2022

Journal Articles

Polyostotic DLBCL Is Characterized By a NF-Κb Pathway Affecting Molecular Profile and Superior Survival

Blood (2022) 140 (Supplement 1): 3534–3536.

https://doi.org/10.1182/blood-2022-159036

Published: 2022

Journal Articles

Harnessing Cell-Free DNA Biological Features for Early Treatment Response Prediction in High Grade B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3529–3531.

https://doi.org/10.1182/blood-2022-168668

Published: 2022

Journal Articles

A Propensity Score-Adjusted Comparison of Lenalidomide + R-CHOP Versus R-CHOP for MYC -Rearranged DLBCL Patients

A. Vera de Jonge, Erik D. van Werkhoven, Avinash G. Dinmohamed, Marcel Nijland, Aeilko H. Zwinderman, Patrick M. Bossuyt, Martine S. Veldhuis, Emma G.G.M. Rutten, Rogier Mous, Joost S.P. Vermaat, Yorick Sandberg, Eva de Jongh, Yavuz M. Bilgin, Rinske Boersma, Harry R. Koene, Marie Jose Kersten, Daphne de Jong, Martine E.D. Chamuleau

Blood (2022) 140 (Supplement 1): 2059–2060.

https://doi.org/10.1182/blood-2022-163204

Published: 2022

Journal Articles

Effects of HLA Mismatches on Cytokine Release Syndrome and Associated Non-Relapse Mortality in Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Peter A. Von Dem Borne, Berit M. Kemps-Mols, Liesbeth C. de Wreede, Adriaan A. van Beek, Tjeerd J.F. Snijders, Danielle van Lammeren, Janneke Tijmensen, Aniko Sijs-Szabo, Theo L. Nering Bögel, Mirjam A. Oudshoorn, Constantijn J.M. Halkes, Peter van Balen, Erik W.A.F. Marijt, Jennifer M.L. Tjon, Joost S.P. Vermaat, Hendrik Veelken

Blood (2022) 140 (Supplement 1): 4735–4736.

https://doi.org/10.1182/blood-2022-157012

Published: 2022

Journal Articles

Prophylactic Donor Lymphocyte Infusion in Patients after Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide Is Associated with Low Relapse Risk and Excellent Survival in Patients below 65 Years with Acute Myeloid Leukemia and High-Risk Myelodysplasia

Peter A. Von Dem Borne, Tjeerd J.F. Snijders, Danielle van Lammeren, Janneke Tijmensen, Erwin V. Planken, Henriette Levenga, Yascha van den Berg, Erik WAF Marijt, Peter van Balen, Jennifer M. Tjon, Joost S.P. Vermaat, Theo L. Nering Bögel, Mirjam A. Oudshoorn, Constantijn J.M. Halkes, Hendrik Veelken

Blood (2022) 140 (Supplement 1): 7742–7743.

https://doi.org/10.1182/blood-2022-157894

Published: 2022

Journal Articles

Outcome of Transformed Marginal Zone Lymphoma: A Population Based Study

Johanna A.A. Bult, Francien Huisman, Yujie Zhong, Nick Veltmaat, Sanne Tonino, Joost S.P. Vermaat, Martine E.D. Chamuleau, Arjan Diepstra, Wouter J. Plattel, Anke Van Den Berg, Mirian Brink, Marcel Nijland

Blood (2022) 140 (Supplement 1): 6514–6516.

https://doi.org/10.1182/blood-2022-166052

Published: 2022

Journal Articles

Special Anatomical Subtypes of Diffuse Large B-Cell Lymphoma Have Distinct Tumor Microenvironments

Blood (2022) 140 (Supplement 1): 164–165.

https://doi.org/10.1182/blood-2022-156103

Published: 2022

Journal Articles

Antigen-Independent, Autonomous B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma

Janneke A. Eken, Marvyn T. Koning, Julieta H. Sepulveda Yanez, Cornelis A.M. van Bergen, Edwin Quinten, Kristyna Kupcova, Ondrej Havranek, Ruben A.L. De Groen, Joost S.P. Vermaat, Daphne de Jong, Philip Kluin, Arjen Cleven, Hassan Jumaa, Hendrik Veelken

Blood (2022) 140 (Supplement 1): 6444–6445.

https://doi.org/10.1182/blood-2022-159420

Published: 2022

NARROW

Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Population-Based External Validation of the CAR-Hematotox Score to Predict CAR T Cell Related Toxicity and Outcome in R/R LBCL Patients

Unveiling Transformation Mechanisms of Nodal Marginal Zone Lymphoma Using a Multi-Omics Approach

Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

Fixed-Duration Epcoritamab + R 2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

Cell-Free DNA Genomic and Fragmentomic Features for Early Outcome Prediction in Diffuse Large B-Cell Lymphoma

Oncogenic CARD11 Mutations and Autonomous BCR Signaling Act As Functionally Equivalent Alternative Drivers in ABC-DLBCL

Immunosuppressed Tumor Microenvironment in MYC -Rearranged High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial

Epcoritamab SC + R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: First Disclosure from Arm 8 of the Epcore NHL-2 Trial

Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5101) in Relapsed/Refractory NHL: Results from the Phase 1 Atalanta-1 Trial

Molecular Diagnostics for TP53 Is Recommended in B-Cell Lymphomas

Polyostotic DLBCL Is Characterized By a NF-Κb Pathway Affecting Molecular Profile and Superior Survival

Harnessing Cell-Free DNA Biological Features for Early Treatment Response Prediction in High Grade B-Cell Lymphoma

A Propensity Score-Adjusted Comparison of Lenalidomide + R-CHOP Versus R-CHOP for MYC -Rearranged DLBCL Patients

Effects of HLA Mismatches on Cytokine Release Syndrome and Associated Non-Relapse Mortality in Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Prophylactic Donor Lymphocyte Infusion in Patients after Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide Is Associated with Low Relapse Risk and Excellent Survival in Patients below 65 Years with Acute Myeloid Leukemia and High-Risk Myelodysplasia

Outcome of Transformed Marginal Zone Lymphoma: A Population Based Study

Special Anatomical Subtypes of Diffuse Large B-Cell Lymphoma Have Distinct Tumor Microenvironments

Antigen-Independent, Autonomous B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only